NR3C2 and Hyperkalemia: Lastly, although hyperkalemia remains a concern with mineralocorticoid receptor antagonists, third-generation mineralocorticoid receptor antagonists such as finerenone may present a more favorable cardiac-to-renal activity ratio and fewer adverse effects.